Articles

  • 2 weeks ago | genengnews.com | John Sterling |John Sterling

    Home Topics Bioprocessing Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease... Credit: Lonza Credit: Lonza Ethris and Lonza agreed to collaborate on the development of room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory diseases.

  • Jan 9, 2025 | upstatebusinessjournal.com | John Sterling

    In the world of sales, where success is quantified by numbers, performance benchmarks stand as the endzones guiding teams toward their goals. Benchmarks are not just numbers on a dashboard; they are the scoreboard to determine who wins. When I was getting started as a sales manager, I struggled to get my ragtag posse of a sales team to do what I wanted. I was frustrated trying to get them to do all the things that would help them sell more.

  • Jan 7, 2025 | genengnews.com | John Sterling

    CDMO WuXi Biologics signed a deal with Candid Therapeutics, a clinical-stage biotechnology company, giving Candid exclusive global rights to a preclinical trispecific T-cell engager discovered on WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBody™. WuXi Biologics is eligible to obtain an upfront payment and development and sales milestones totaling up to $925 million as well as royalties.

  • Dec 18, 2024 | genengnews.com | John Sterling

    The process by which fungi synthesize some of their most potent compounds has remained unclear for many years. This is especially true of cyclopentachromone, a key building block in fungal products whose derivatives have shown promise in fighting cancer and reducing inflammation, among other medicinal properties. While chemists have made progress in creating chromone derivatives in the lab, the molecule’s distinctive structure has proven difficult to copy precisely and reliably.

  • Dec 17, 2024 | genengnews.com | John Sterling

    University of Pennsylvania School of Engineering and Applied Science engineers say they have modified lipid nanoparticles (LNPs) to not only cross the blood-brain barrier (BBB) but also to target specific types of cells, including neurons.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →